Randomized trial · people

Ecnoglutide: well tolerated weekly for 6 weeks in a phase 1 trial

Checked against the paper Randomized trialPublished by PepVault

The takeaway

This study shows ecnoglutide lasts long enough in the body for once-weekly shots and was generally tolerated in healthy people over 6 weeks, while its edge over semaglutide on weight was seen only in rodents.

Kind
Randomized trial
Studied in
People
Published
2023
Journal
Mol Metab

What they tested

The team set out to describe how ecnoglutide (XW003), a new GLP-1 analog, behaves in cell tests and rodents, and how safe it is and how long it lasts in healthy people.

How the study was done

Ecnoglutide was tested in cell-based GLP-1 receptor signaling assays, in db/db mice and in diet-induced obese rats. It was then given in a phase 1, double-blind, randomized, placebo-controlled trial (placebo, a dummy shot) in healthy people, using single doses from 0.03 to 1.0 mg and weekly doses from 0.2 to 0.6 mg for 6 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking ecnoglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In cell tests, ecnoglutide strongly triggered cAMP, a signal inside the cell (EC50 = 0.018 nM, the dose giving half the maximum effect), but barely caused the GLP-1 receptor to be pulled into the cell (EC50 > 10 μM). In mice and rats, it lowered blood glucose, raised insulin and led to more body weight loss than semaglutide. In healthy people, weekly shots for up to 6 weeks were generally safe and well tolerated, with decreased appetite, nausea and headache among the side effects. Its half-life at steady state, the time for the drug level to fall by half, was 124 to 138 h.

What it doesn’t show

The blood sugar, insulin and weight results come from mice and rats, not people. The human part was an early-stage trial in healthy people lasting at most 6 weeks, and it measured safety and drug levels rather than weight loss or blood sugar control.

The paper

Guo et al. Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol Metab. 2023.

The compound

More studies on Ecnoglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking ecnoglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo